`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`FORD MOTOR COMPANY
`
`Petitioner
`
`V.
`
`VERSATA DEVELOPMENT GROUP, INC.
`
`Patent Owner.
`
`Case CBMZOlé—OOIOO
`
`Patent No. 8,805,825
`
`VERSATA’S OPPOSITION TO FORD’S REQUEST FOR REHEARING
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`US. Patent and Trademark Office
`
`PO. Box 1450
`
`Alexandria, VA 22313—l450
`
`
`
`Page 1
`
`CBM2016—00100
`Patent No. 8,805,825
`
`To succeed on rehearing, Ford must demonstrate that the Board abused its
`
`discretion in declining to institute this CBM proceeding. See 37 C.F.R. § 42.71(c).
`
`Ford does not acknowledge or meet this burden. Ford’s rehearing request hinges on
`
`a case—Rembrandt Wireless Techs., LP 12. Samsung Electronics Co., Ltd, 2017
`
`WL 1370089 (Fed. Cir. Apr. 17, 2017)——that has nothing to do with the scope of
`
`CBM patent review; as such,
`
`the Board could not have misapprehended or
`
`overlooked it in deciding whether to institute. Rembrandt interprets the marking
`
`requirement in 35 U.S.C. § 287, which has an entirely different purpose, entirely
`
`different language, and an entirely different effect than the requirements for CBM
`
`review in § 18 of the AIA. F ord’s rehearing request should be denied.
`
`I.
`
`Disclaimer of A Claim Under 35 U.S.C. § 253(a) Causes The Claim to
`Be Treated As If It Had Never Existed For Jurisdictional Purposes.
`
`The Federal Circuit has made clear that disclaimer of claims under 35
`
`U.S.C. § 253 “effectively eliminate[s]
`
`those claims from the original patent.”
`
`Vectra Fitness, Inc. v. TNWK Corp, 162 F.3d 1379, 1383 (Fed. Cir. 1998). Thus,
`
`upon a disclaimer under§ 253, the disclaimed claims are treated as though they
`
`had “never existed.” Genetics Inst, LLC v. Novartis Vaccines & Diagnostics, Inc,
`
`655 F.3d 1291, 1299 (Fed. Cir. 2011). That is because, “[u]pon the filing of the
`
`disclaimers, the original claims were withdrawn from the protection of the patent
`
`laws.” Altoona Publix Theatres v. Am. Tri-Ergon Corp, 294 US. 477, 492 (1935).
`
`Because the disclaimed claims “never existed,” a tribunal’s jurisdiction
`
`cannot be based on those claims. For example, courts routinely dismiss cases for
`
`want of jurisdiction when the claims of the patent—in—suit are disclaimed. See
`
`
`
`Page 2
`
`CBM2016—00100
`Patent No. 8,805,825
`
`Merck & Ca, Inc. V. Apotex, Inc., 2007 WL 4082616, at *5 (D.N.J. NOV. 15,
`
`2007), afl’a’, 292 F. App’x 38 (Fed. Cir. 2008) (finding no jurisdiction, “because
`
`Merck has formally disclaimed the ’735 and ’443 patents, and can no longer
`
`enforce any claims as to these patents”); 3V, Inc. v. CIBA Specialty Chemicals
`
`Corp, 587 F. Supp. 2d 641, 645—46 (D. Del. 2008) (same).
`
`Like court proceedings, CBM proceedings are “adversarial [in] nature,” PPC
`
`Broadband, Inc. v. Corning Optical Comrnc’ns RF, LLC, 815 F.3d 734, 741 (Fed.
`
`Cir. 2016), and the Board has a strictly limited jurisdiction over them, Versata Dev.
`
`Grp., Inc. v. SAP Am, Inc., 793 F.3d 1306, 1320 (Fed. Cir. 2015). And, just as a
`
`court’s jurisdiction cannot be based on disclaimed claims, the Board’s jurisdiction
`
`over CBM proceedings cannot be predicated on disclaimed claims.
`
`The Office
`
`explicitly
`
`recognized
`
`this
`
`jurisdictional
`
`limitation
`
`in
`
`promulgating 37 C.F.R. § 42.207(e). That regulation, which falls under the heading
`
`“preliminary response to petition,” provides that, in response to a petition, “[t]he
`
`patent owner may file a statutory disclaimer
`
`disclaiming one or more claims in
`
`the patent. No post-grant review will be instituted based on disclaimed claims.”
`
`The plain meaning of these words is that a post—grant review (including a CBM
`
`proceeding) cannot be instituted based on a disclaimed claim.1
`
`Here,
`
`in response to Ford’s petition and in accordance with § 42.207(e),
`
`1 This regulation does not mean only that a CBM proceeding cannot be
`
`instituted “on” a disclaimed claim. That would improperly “read[] language out of
`
`the regulation.” Gose v. US. Postal Serv., 451 F.3d 831, 840 (Fed. Cir. 2006).
`
`
`
`Page 3
`
`CBM2016—00100
`Patent No. 8,805,825
`
`Versata disclaimed any claim that could plausibly come within the scope of a
`
`covered business method patent.2 Thus, the Board did not abuse its discretion in
`
`declining to institute this CBM review. See Broadsign Int ’1, LLC v. T~Rex Property
`
`AB, No. CBM2017—00008, Paper 7 (Apr. 26, 2017) (declining to institute CBM
`
`proceeding based on disclaimed claims post-Rembrandt).
`
`II.
`
`Rembrandt Is Irrelevant To Whether The Board Has Jurisdiction To
`
`Institute A CBM Proceeding.
`
`Despite this clear rule, Ford argues that the decision in Rembrandt requires
`
`the Board to institute review based on the disclaimed claims. It does not.
`
`Rembrandt concerned the marking statute. That statute is not a jurisdictional
`
`limitation on a court. Rather, it is a permissive statute under which, if a patentee
`
`wishes to obtain pre—notice damages, the patentee must mark its products that
`
`practice the patent. Rembrandt, 2017 WL 1370089, at *8. The statute’s goal is to
`
`ensure that the public has a right to practice an unmarked feature of a device until
`
`it has notice of the patent. Id. at *9. In accord with that notice function, § 287 is
`
`written broadly to require notice sufficient to trigger damages whenever anyone is
`
`“making, offering for sale, or selling within the United States any patented article.”
`
`2 Pursuant to the Board’s order on briefing [Paper 14], Versata limits its
`
`arguments to addressing the Federal Circuit’s decision in Rembrandt. Versata
`
`notes, however, that adopting Ford’s arguments on why the non—disclaimed claims
`
`fall within the scope of CBM review would vitiate the Federal Circuit’s decision in
`
`Unwired Planet, LLC v. Google, Inc, 841 F.3d 1376 (Fed. Cir. 2016).
`
`
`
`Page 4
`
`CBM2016-00100
`Patent No. 8,805,825
`
`35 U.S.C.
`
`§ 287(a). The Federal Circuit held that
`
`it would “undermine[] the
`
`marking statute’s public notice function” if a patentee could retroactively undo its
`
`obligation to mark by disclaiming a practiced claim. Rembrandt, 2017 WL
`
`1370089, at *9. The point is that the patentee did, at one time, make an article that
`
`practiced an existing claim, and the public was entitled to copy that article until
`
`given notice—and the patentee cannot use disclaimer to avoid giving that notice.3
`
`In contrast, there is no “public notice” contemplated by § 18 of the AIA.
`
`Either a patent falls in the scope of CBM review or it does not. The public does not
`
`have investment-backed expectations of whether a patent claim is eligible for CBM
`
`review. Further, disclaimer of a claim cannot retroactively create any unfairness to
`
`the public. On the contrary, disclaimers best serve the public by dedicating the
`
`claimed inventions to the public. The Board should not discourage such
`
`disclaimers by allowing disclaimed claims to be used as the basis for CBM review.
`
`Date: May 9, 2017
`
`By:
`
`W
`
`Robert Greene Sterne (Reg. No. 28,912)
`Lead Counsel for Patent Owner
`
`3 The other case cited by Ford—Guinn v. Kopf, 96 F.3d 1419 (Fed. Cir.
`
`l996)—is also irrelevant. In that case, unlike here, the patentee did not disclaim
`
`the claims until after declaration of the interference. Id. at 1421. The Federal
`
`Circuit held that the broad statute giving the Office the power to declare an
`
`interference allowed the Office to enter an adverse final judgment against a
`
`patentee who disclaimed the only claim in the interference. Id. at 1422. And, unlike
`
`here, there was no regulation such as § 42.207(e) limiting the Office’s jurisdiction.
`
`
`
`CERTIFICATE OF SERVICE 137 C.F.R. § 42.6gen
`
`The undersigned hereby certifies that a true and correct copy Of the enclosed
`
`VERSATA’S OPPOSITION TO FORD’S REQUEST FOR REHEARING
`
`was served electronically Via e—mail on May 9, 2017 in its entirety on the following
`
`counsel of record for Petitioner:
`
`Christopher C. Smith (Lead Counsel)
`Thomas A. Lewry (Back—up Counsel)
`John S. LeRoy (Back-up Counsel)
`Frank A. Angileri (Back—up Counsel)
`John P. Rondini (Back—up Counsel)
`Jonathan D. Nikkila (Back-up Counsel)
`BROOKS KUSHMAN RC.
`
`1000 Town Center, Twenty-Second Floor
`Southfield, Michigan 48075
`FPGP013 OCBMRl @brookskushmancom
`
`Respectfully submitted,
`
`Date: May 9, 2017
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`1 100 NEW YORK AVENUE, NW
`
`WASHINGTON, DC. 20005
`
`(202) 371 -2600
`
`Lead Counselfor Patent Owner
`Versata Development Group, Inc.
`
`